Board of Directors

• Eckard Weber, MD
• Lou Bock
• Marc Lippman, MD
• Mike Powell, PhD
• Norman Selby
• Drew Senyei, MD
• Mel Sorensen, MD

Founders

• Marc Lippman, MD
• Shaomeng Wang, PhD
• Dajun Yang, MD, PhD

Management

• Mel Sorensen, MD
• Lance Leopold, MD
• Joel F. Sussman, CPA
• Ming Guo, PhD
• Dajun Yang, MD, PhD
• Shaomeng Wang, PhD

• Introduction and Scientific Approach
• Clinical Portfolio
• AT-101: Bcl-2 Inhibitor
• AT-406: IAP Inhibitor
• HDM2 Inhibitor 

Active Clinical trials

• AT-101 in Hormone-Refractory Prostate Cancer (HRPC)
• AT-101 in Gastrointestinal (Esophageal) Cancer

Clinical Trial Enrollment

Key Clinical Programs

• Proof-of-Concept Established in the Clinic with AT-101 in HRPC
• Chemotherapy-Naïve Hormone-Refractory Prostate Cancer (HRPC)
• Docetaxel-Resistant Hormone-Refractory Prostate Cancer (HRPC)
• Hormone-Refractory Prostate Cancer (HRPC)

Clinical Trial FAQs

• Funding
• Company Fact Sheet